edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Cantargia has announced that the US Patent and Trademark Office has granted the patent related to its lead candidate, nadunolimab. The patent covers the use of nadunolimab as a potential medicine in combination with chemotherapy and/or immunotherapy. We note that the lead indication being targeted is pancreatic ductal adenocarcinoma in combination with chemotherapy; this will be protected by the new patent. The patent is valid until 2035, excluding any potential extensions.
Industrials | Comment
TMT | Comment
Industrials | Comment
Industrials | Comment
Get access to the very latest content matched to your personal investment style.